TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06635785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-081
Description: AI-081 is a humanized monoclonal antibody with a silenced Fc targeting PD-1 and VEGF.
Study: NCT06123208

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole cooked pinto bean
Description: Meal comprised of whole cooked pinto beans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pinto bean flour
Description: Meal comprised of pinto bean flour

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control meal
Study: NCT06258668

Intervention type: DRUG
Intervention: Deucravacitinib
Description: As per product label
Study: NCT06211907

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Postoperative intraocular tamponade
Description: Flushing the eye cavity with a tamponade at the end of surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative intraocular tamponade
Description: Flushing the eye cavity with a tamponade at the end of surgery
Study: NCT05371288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH)
Description: Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms.
Study: NCT05408559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
Study: NCT04500613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Erector Spinae Plane Block with bupivacaine and dexamethasone
Description: Bupivacaine is administered typically to reduce sensation in an area. It acts as a nerve block for surgical procedures. Dexamethasone is a corticosteroid that reduces inflammation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No bilateral Erector Spinae Plane Block (no bupivacaine and no dexamethasone)
Description: Patients who are randomized to this group will not receive a bilateral erector spinae plane block
Study: NCT06037278

Intervention type: DEVICE
Group type: OTHER
Intervention: MyPAO
Description: use of MyPAO surgical guide to support periacetabular osteotomy procedures for treatment of acetabular dysplasia
Study: NCT06020716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution
Description: Three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution
Description: Three times daily
Study: NCT06013995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days
Study: NCT05408559

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulforaphane
Description: Caplets containing SFN-rich broccoli sprout extracts or placebo caplets containing microcrystalline cellulose will be obtained from from Nutramax Labs.
Study: NCT05099575

Intervention type: DRUG
Intervention: Syntocinon, papal, misotac
Description: Using different drugs to prevent atonic PPH during CD in high risk group

Intervention type: DRUG
Intervention: Syntocinon, papal, misotac
Description: Using different drugs to prevent atonic PPH during CD in high risk group

Intervention type: DRUG
Intervention: Syntocinon, papal, misotac
Description: Using different drugs to prevent atonic PPH during CD in high risk group

Intervention type: DRUG
Intervention: Syntocinon, papal, misotac
Description: Using different drugs to prevent atonic PPH during CD in high risk group
Study: NCT06188195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ACS intervention were used in the experimental group
Study: NCT04955002

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06020716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 400 Mg-57 Mg/5 mL Oral Powder for Reconstitution
Description: Three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Three times daily
Study: NCT05295030

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breast milk
Description: Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
Study: NCT04296019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Maintenance therapy with fruquintinib ( 5 mg qd for 3 consecutive weeks, followed by discontinuation for 1 week).
Study: NCT06182462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Distraction
Description: The experimental group will receive a VR video game called DREAM DENTAL designed specifically for this study. Pharmaceutical treatment during the procedure such as the use of injected local anesthesia will be used if the procedure requires. Children will be able to play for the entire duration of the dental procedure. The VR video game aims at reducing anxiety in children aged 6 to 17 years old by means of immersive distraction. The VR headset offers children with the ability of viewing the game they are playing in real time while simultaneously obstructing the partial view they would normally have of the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant or resident dentist. One parent will be allowed in the room during the dental procedure and their presence will be recorded.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Clinic's Standard Treatment
Description: The control group will only receive a care-as-usual approach. This includes viewing cartoons on a muted mounted television set and the use of pharmaceutical treatment during the procedure such as the use of injected local anesthesia, according to the procedure. In the event of non-cooperation during the appointment, any retake or re-scheduling appointments will be compiled by the research assistant. One parent will be permitted to be present in the room during the procedure as part of the clinic's usual protocol and their presence will be recorded. Children allocated to the control group will be offered the possibility to try the VR game after the study period if they choose to do so.
Study: NCT05147688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study: NCT06533878

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: OTHER
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg
Study: NCT05295030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kieember Infant formula, Ruibuen®
Description: Kieember Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by (1) OPO structured lipid of the third generation; and (2) Breast Milk Simulated complete structured lipid UPU. It was produced by Yashili New Zealand Dairy Co., Limited

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yashili Infant formula, Ruibuen®
Description: Yashili Infant formula, Ruibuen®: a type of Phase I infant formula for 0-6 month infants, with a trademark of Ruibuen®. The formula is characterized by(1) lactoferrin and(2) lutein . It was produced by Yashili International Holdings Ltd.,China
Study: NCT06533878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209 placebo
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209 placebo
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209 placebo
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HY-209 placebo
Description: Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg
Study: NCT05480293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: ranibizumab，0.5mg,IVT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT510A
Description: SCT510A，1.25mg,IVT
Study: NCT06043817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (Escalated)
Description: STX-721 dose will be escalated per cBLRM-design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (2 doses)
Description: Participants will receive STX-721 at one of two doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STX-721 (RP2D)
Description: Participants will receive the RP2D of STX-721.
Study: NCT06119217

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TTX-030, budigalimab, nab-paclitaxel and gemcitabine
Description: Dose and schedule per protocol

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel and gemcitabine
Description: Dose and schedule per protocol
Study: NCT05323656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Setanaxib
Description: Oral tablets, 400 mg per tablet

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study: NCT04970914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: 12mg, continuous oral 2 weeks stop for 1 week, 21 days for a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab
Description: Penpulimab 200 mg administered intravenously every 3 weeks.
Study: NCT05563181

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control bar code label
Description: Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control bar code label
Description: Viewing beverages that contain control labels (i.e., bar codes) on sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning label
Description: Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages
Study: NCT05678140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: soft tissue mobilization
Description: soft tissue mobilization; For the shoulder area, the application will take between 3-5 minutes. Instrumental Soft tissue mobilization will be performed while the participant is sitting in a supported chair, parallel to the shoulder and scapular muscle fibers and at an angle of 45 degrees to the vertical. Patients will be told that there may be small red spots called petechiae in the treated area. The application will be made using Graston iron rods.
Study: NCT06463548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride liposome injection
Description: Irinotecan hydrochloride liposome injection (70mg/m2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (850 mg/m2) will be administered orally in a 2-week treatment cycle, twice a day from day 1 to day 10 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib (8 mg) will be administered orally in a 2-week treatment cycle, once a day from day 1 to day 14 of each cycle
Study: NCT05016869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib plus capecitabine
Description: Ⅰb: capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W; fruquintinib 3mg/4mg/5mg, d1-14, PO QD, Q3W.~ⅠⅠ: fruquintinib RP2D, d1-14, PO QD, Q3W, capecitabine: 1000 mg/m²，PO BID, d1-14，Q3W
Study: NCT04958421

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PiCSO Impulse System
Description: After blood flow restoration, the subjects meeting all eligibility criteria will be enrolled into the study and randomized either to PiCSO Group or Control Group. If the subject is randomized to PiCSO Group, the coronary sinus (CS) will be cannulated through the femoral vein and the PiCSO Impulse Catheter will be placed in the CS. Once PiCSO Impulse Catheter is placed into CS, PiCSO treatment is started followed by stenting. The physician shall target a PiCSO treatment of 45 minutes whereas the treatment should be continued during and post stent insertion. At the end of the PiCSO treatment, the PiCSO Impulse Console is stopped and the PiCSO Impulse Catheter is removed.
Study: NCT06376266

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: nutritional supplements
Description: a daily supplement of branched-chain amino acids combined with medium-chain triglycerides

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: nutritional supplements
Description: a daily supplement of branched-chain amino acids combined with medium-chain triglycerides
Study: NCT04673136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI-GENIUS Medtronic
Description: Colonoscopy assisted by GI-GENIUS device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Colonoscopy
Description: Standard colonoscopy
Study: NCT05731466

Intervention type: DEVICE
Group type: OTHER
Intervention: CardioMems HF System
Description: 1. Implantation CardioMems device.~2. Evaluation of right ventricular-arterial coupling during exercise using a hybrid technique of real-time CMR-derived volume measures and CardioMems-derived pulmonary artery pressure measurements.
Study: NCT05563181

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Warning label
Description: Viewing beverages that contain an added-sugar warning label (icon-plus-text yellow label that says, WARNING: High in added sugar, on sugar-sweetened beverages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational campaign poster about added-sugar warning labels
Description: Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational campaign poster about added-sugar warning labels
Description: Viewing an informational campaign about added-sugar warning labels. The poster will be shown in Spanish (instead of English) if the participant reports speaking and reading in Spanish better than English.
Study: NCT04844021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge
Description: EHR-based nudge

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nudge+
Description: EHR-based nudge plus facilitation
Study: NCT04916496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based lifestyle counselling programme
Description: The ACT-LCP Group will receive an ACT-based lifestyle counselling programme, which composes of 5-weekly group sessions (2 hours per each, 15 hours in total). Acceptance, mindfulness, values clarification skills/exercises will be used to help patients to increase self-perspective taking and willingness to experience distressing sensations, discomfort and urges while engaging in healthy lifestyle behaviours.~One month after the programme, the participant will receive one 'booster' session (2 hours), followed by 2-weekly telephone follow-up calls (20-30 minutes per call) to evaluate the effort of behavioural change.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Healthy lifestyle talk
Description: The Control Group will receive one 2-hour, healthy lifestyle education talk (at least 10 patients in the talk) based on the HEARTS technical package as recommended by the WHO as routine care. This package includes a collection of evidence-based protocols which standardizes a clinical approach to promote a healthy lifestyle among adults. The Control Group will receive routine psychiatric outpatient/rehabilitation services as provided by the clinic in NDH/community centre.~One month after the talk, three weekly follow-up telephone calls (20-30 minutes) will be arranged for each patient in the Control Group to evaluate the effort of behavioural change.
Study: NCT04880720

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling - 10mL

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling - 10mL

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling - 10mL
Study: NCT06139718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT Guide Lite
Description: ACT Guide Lite is a single session online mental health program that is designed to take 30-45 minutes to complete. The single session self-guided intervention includes a series of sections that teach key ACT skills.
Study: NCT06023862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: Intravenous (IV) infusion
Study: NCT05678140

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy
Description: Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: Hot-pack to warm the superficial tissue, TENS for pain relief, ultrasound (US) to warm the joint structures before mobilization techniques, ROM, stretching, and isometric strengthening exercises to restore joint mobility and function of the shoulder area
Study: NCT05548426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B, Linezolid 10d
Description: Oral Linezolid 600mg, taken twice a day for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A, Penicillin
Description: Standard of care benzathine penicillin G, one intramuscular injection, 2.4MU
Study: NCT05471414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-food, Plant-Based Diet
Description: Pre-packaged, plant-based meals (prepared by Plantable) will be delivered weekly to participants' homes for 8 weeks. Meals are made with whole ingredients including whole grains, vegetables, legumes, nuts and seeds. Added sugar, animal-based products, refined grains, and processed foods are not used in any meal. Participants will be coached via phone calls, SMS, emails, and the app throughout the intervention to prepare meals in accordance with the diet. Participants will have access to a Registered Dietitian. During the first 4 weeks, 12 meals/week will be provided to participants; followed by 6 meals/week for the next 4 weeks; followed by 18 weeks where participants will continue to receive coaching, but will be expected to make all their own whole-food, plant-based meals using Plantable's assistance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Nutritional Counseling
Description: All study participants will receive consult with a Registered Dietitian at the Baseline visit and visit 1 study assessments. After visit 1, study participants assigned to the general nutritional counseling arm will receive an additional in-person or telehealth consultation with a Registered Dietitian that will consist of identification and counseling to improve diet quality and achieve a healthy body weight consistent with American Cancer Society guidelines.~Study participants in the control group will continue to receive general nutritional counseling and education with weekly scheduled telephone consultations with a Registered Dietitian for the first 4 weeks of the study period. For the remainder of the study period, they will receive counseling and education from Registered Dietitians via monthly scheduled phone calls.